Macular Telangiectasia Type 2 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Macular Telangiectasia Type 2 Market Outlook
Thelansis’s “Macular Telangiectasia
Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Macular Telangiectasia Type 2
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Macular
Telangiectasia Type 2 Overview
Macular
telangiectasia (MacTel) type 2 is a bilateral retinal disorder of unknown
etiology, characterized by distinct alterations in the macular capillary
network and neurosensory atrophy. Initially, the disease manifests temporally
to the foveal center and may expand to encompass an oval region with
approximate dimensions of 6° horizontally and 5° vertically centered on the
foveola. The onset of symptoms typically occurs during the fifth or sixth
decade of life, and a subset of patients reports a positive family history. Due
to limited awareness among both clinicians and patients, MacTel type 2 is often
diagnosed belatedly and may be misidentified as age-related macular
degeneration in cases involving neovascularization. The prevalence of MacTel
type 2 is rare, estimated at approximately 0.10%, with no significant gender or
racial predilections. The mean age of onset is approximately 55 years. Notably,
up to 45% of individuals with MacTel type 2 also present with comorbid
conditions such as diabetes mellitus, obesity, hypertension, or cardiovascular
diseases, which, along with smoking, may elevate the risk of clinical
manifestation.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment